NDAORALCAPSULEPriority Review
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
5/8 — Partial
Priority Review
RYDAPT (rydapt) by Novartis is receptor tyrosine kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2017.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYDAPT is an oral receptor tyrosine kinase inhibitor approved in April 2017 by Novartis for oncology indications. It works by blocking multiple kinase pathways to inhibit tumor cell growth and proliferation. The drug is formulated as an oral capsule for systemic delivery.
$0.031BPart D
PeakStable
4.1 years to LOERYDAPT is in peak lifecycle stage with modest Part D spending ($31M in 2023), suggesting a mature, niche product with a lean commercial team focused on maintenance and specialty oncology channels.
Mechanism of Action
Receptor Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on RYDAPT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.